Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.62 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7377089 | 0.96 | OPRM1 (0.67) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL626042 | 0.95 | OPRM1 (0.65) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL31441136 | 0.95 | OPRM1 (0.65) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL4826627 | 0.92 | OPRM1 (0.71) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL16691415 | 0.84 | OPRM1 (0.66) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL4657416 | 0.84 | OPRM1 (0.61) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL625114 | 0.84 | OPRM1 (0.61) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL13253863 | 0.83 | SLC6A4 (0.56) | OPRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3519672 | 0.83 | OPRM1 (0.60) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 | |
| SCHEMBL17452483 | 0.82 | OPRM1 (0.58) | OPRM1SLC6A4SLC6A3OPRL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| US-20180273495-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-27 | — | — | US | disclosed |
| EP-3362445-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-08-22 | — | — | EP | disclosed |
| US-4806570-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4767790-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| EP-0191542-B1 | ARYLCYCLOBUTYLALKYL AMINES AND THEIR USE AS ANTIDEPRESSIVE MEDICINES | The Boots Company PLC (GB) | 1988-06-08 | — | — | EP | disclosed |
| US-4746680-A | ANTIDEPRESSANTS | THE BOOTS COMPANY P.L.C. (GB) | 1988-05-24 | — | — | US | disclosed |
| US-4629727-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1986-12-16 | — | — | US | disclosed |
| EP-0191542-A1 | Arylcyclobutylalkyl amines and their use as antidepressive medicines | The Boots Company PLC (GB) | 1986-08-20 | — | — | EP | disclosed |
| EP-0111994-B1 | (1-ARYLCYCLOBUTYL) ALKYLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1986-02-26 | — | — | EP | disclosed |
| EP-0108488-B1 | (1-ARYLCYCLOBUTYL) (HETEROCYCLYL) METHYLAMINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1986-02-26 | — | — | EP | disclosed |
| US-4522828-A | CYCLOBUTYLALKYLAMINE COMPOUNDS, ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| EP-0111994-A1 | (1-Arylcyclobutyl) alkylamine derivatives, their preparation and their use as therapeutic agents | The Boots Company PLC (GB) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | OPRM1 4486/4885SLC6A4 4629/4885SLC6A3 4403/4885 |
| US-20180273495-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | OPRM1 4105/4885SLC6A4 3090/4885SLC6A3 3342/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | OPRM1 3420/4885SLC6A4 2584/4885SLC6A3 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.